Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

Open access
Vera-Badillo, F.E., Shapiro, R., Ocana, A., Amir, E., Tannock, I.F. · 2013 · Annals of Oncology

Abstract

Background Phase III randomized, clinical trials (RCTs) assess clinically important differences in end points that reflect benefit to patients. Here, we evaluate the quality of reporting of the primary end point (PE) and of toxicity in RCTs for breast cancer.Methods PUBMED was searched from 1995 to 2011 to identify RCTs for breast cancer. Bias in the reporting of the PE and of toxicity was assessed using pre-designed algorithms. Associations of bias with the Journal Impact Factor (JIF), changes in the PE compared with information in ClinicalTrials.gov and funding source were evaluated.Results Of 164 included trials, 33% showed bias in reporting of the PE and 67% in the reporting of toxicity. The PE was more likely to be reported in the concluding statement of the abstract when significant differences favoring the experimental arm were shown; 59% of 92 trials with a negative PE used secondary end points to suggest benefit of experimental therapy. Only 32% of articles indicated the frequency of grade 3 and 4 toxicities in the abstract. A positive PE was associated with under-reporting of toxicity.Conclusion Bias in reporting of outcome is common for studies with negative PEs. Reporting of toxicity is poor, especially for studies with positive PEs.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mds636

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Ocana, 2011, When are ‘positive’ clinical trials in oncology truly positive?, J Natl Cancer Inst, 103, 16, 10.1093/jnci/djq463 · DOI · Paper page

Cited by

See all 120

Metadata

Authors
Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F.
Affiliations
University of Toronto (CA)
Corresponding author
Tannock, I.F.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2013-05
Volume
24
Issue
5
Pages
1238-1244
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2120241552
Cited by
117
References
27
Citations by year
2026: 3 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 13 · 2018: 11 · 2017: 8 · 2016: 13 · 2015: 13 · 2014: 14 · 2013: 18
FWCI
21.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords
breast cancer, reporting bias, primary endpoint, adverse event reporting, randomized controlled trials, women, abstract reporting, negative trial results, funding disclosure
MeSH terms
Algorithms, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Research Design, Observer Variation, Bias, Randomized Controlled Trials as Topic, Journal Impact Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mds636
The paper
Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F. (2013). Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mds636

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.